ABCL Q2 2020 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+352.9% YoY

Gross Profit

$11M100.0% margin

Operating Income

-$854,000-7.6% margin

Net Income

$7M59.7% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+141.1%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$22M

Stock-Based Comp.

$606,000

Balance Sheet

Total Assets

$155M

Total Liabilities

$64M

Stockholders' Equity

$91M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$2M	+352.9%
Gross Profit	$11M	$468,009	+2299.1%
Operating Income	-$854,000	-$712,714	-19.8%
Net Income	$7M	-$302,883	+2313.1%